The case in point is the aforementioned recent study where EVs released systemically from non-metastatic cancer cells were found to reprogram patrolling monocytes, leading to upregulation of pigment epithelium-derived factor (PEDF), which is a potent inhibitor of angiogenesis. The gene discussed is SERPINF1; the disease is cancer.